---
title: "MYRIAD GENETICS INC 2026: Revenue $190.7M, EPS ($0.46) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294511526.md"
description: "Myriad Genetics Inc reported Q2 2026 results with revenue of $190.7M, down 10.5% YoY due to lower reimbursement and estimate adjustments. The company posted a net loss of $43.2M, significantly improved from the prior year's $330.5M loss, resulting in diluted EPS of ($0.46). While cancer volumes rose 9%, prenatal volumes fell 11%. Myriad increased commercial investment and appointed a new CTO to boost efficiency."
datetime: "2026-07-31T12:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294511526.md)
  - [en](https://longbridge.com/en/news/294511526.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294511526.md)
generator: "portal-rs"
---

# MYRIAD GENETICS INC 2026: Revenue $190.7M, EPS ($0.46) — 10-Q Summary

Myriad Genetics Inc reported results for the 2026 quarter with revenue of $190.7M, a net loss of ($43.2M) and diluted loss per share of ($0.46), reflecting lower revenue and improved loss versus the prior-year quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$190.7M

$213.1M

(10.5%)

Net income²

($43.2M)

($330.5M)

86.9%

Diluted EPS³

($0.46)

($3.57)

87.1%

*¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.*

**Business Highlights**

-   Revenue trends: Total revenue declined year‑over‑year (YTD roughly $391.1M vs $409.0M) driven by lower reimbursement and estimate adjustments.
-   Channel and volume mix: Cancer volumes increased about 9% YTD while Prenatal volumes fell roughly 11%; Mental Health volumes grew about 5%.
-   Pricing and reimbursement: Revenue per test declined across Cancer Care and Prenatal segments due to reimbursement reductions.
-   Commercial investment: Increased sales and marketing spend to expand commercial reach; launched Prolaris + AI and expanded Precise MRD offerings.
-   Operational focus: Engaged professional services to boost efficiency, appointed a new CTO, and expanded clinical evidence to support scale.

Original SEC Filing: MYRIAD GENETICS INC \[ MYGN \] - 10-Q - Jul. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)

## Related News & Research

- [Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference | VNRX Stock News](https://longbridge.com/en/news/298594142.md)
- [The 'Godfather of AI' says it's not 'unreasonable' to believe there's a 10% chance the technology will end humanity](https://longbridge.com/en/news/298619963.md)
- [abrdn Australia Equity Fund NAV at $10.63 as of Sept. 10, 2026](https://longbridge.com/en/news/298745554.md)
- [VolitionRx presents early stage I solid cancer detection data for Capture-Seq at ESMO MAP conference](https://longbridge.com/en/news/298592775.md)
- [Top 10 in the Nation, No. 1 in California: Children’s Hospital Los Angeles Again Honored for Excellence in Care](https://longbridge.com/en/news/298996711.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**